Drug use-results survey of TECVAYLI Subcutaneous Injection in patients with relapsed or refractory multiple myeloma (limited to patients who are refractory to standard treatments)

Drug use-results survey of TECVAYLI Subcutaneous Injection (relapsed or refractory multiple myeloma) - TEC1U

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058084

Enrollment

100

Registered

2025-06-16

Start date

2025-06-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractory multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with relapsed or refractory multiple myeloma (limit the use to patients who are refractory or intolerant to standard treatments) who have received this drug in accordance with the approved indication and dosage and administration for the first time.

Exclusion criteria

Exclusion criteria: After conclusion of the contract, the investigator will enter patient information through the "Patient Registration Screen" in the EDC system within 30 days after the start date of treatment with this drug (the start date of treatment with this drug is regarded as Day 1).

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Events,Adverse reactions)	—

Countries

Japan

Contacts

Public ContactHirokazu Shirai

Janssen Pharmaceuticals K.K. Medical Affairs Delivery Unit

hshirai3@its.jnj.com070-4179-4492

Outcome results